Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques

Breast Cancer Research and Treatment

Volumn 48, Issue 3, 1998, Pages 221-229

  Cline, J Mark ^a   Soderqvist, Gunnar ^b   Von Schoultz, Eva ^b   Skoog, Lambert ^b   Von Schoultz, Bo ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Conjugated estrogens; Estrogen receptor; Macaques; Medroxyprogesterone acetate; Progesterone receptor; Proliferation; Tamoxifen

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; AUTOPSY; BREAST EPITHELIUM; CELL PROLIFERATION; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MACACA; MAMMARY GLAND; MORPHOMETRICS; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST; ESTROGENS, CONJUGATED (USP); FEMALE; KI-67 ANTIGEN; MACACA; MEDROXYPROGESTERONE 17-ACETATE; OVARIECTOMY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 0031897755     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005984932268     Document Type: Article

References (42)

1. Vihko R, Isomaa V: Endocrine aspects of endometrial cancer. In: Voight K, Knabbe C (eds) Endocrine Dependent Tumors. Raven Press, Ltd., New York, 1989, pp 197-212
2. Pike M: Hormonal contraception with LHRH agonists and the prevention of breast and ovarian cancer. In: Mann R (ed) Oral Contraceptives and Breast Cancer. Parthenon Publishing Group, Lancaster, England, 1990, pp 323-348
3. Key TJ, Pike MC: The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57: 205-212, 1988
4. Gompel A, Malet C, Spritzer P, Lalardrie JP, Kuttenn F, Mauvais-Jarvis P: Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 63: 1174-1180, 1986
5. Mauvais-Jarvis P, Kuttenn F, Gompel A: Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat 8: 179-188, 1986
6. Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ: Oral contraceptive use influences resting breast proliferation. Hum Pathol 20: 1139-1144, 1989
7. Longacre TA, Bartow SA: A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 10: 382-393, 1986
8. Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M, Howell A: The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58: 163-170, 1988
9. Vogel PM, Georgiade NG, Fetter BF, Vogel FS, McCarty KS Jr: The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 104: 23-34, 1981
10. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589-1593, 1995
11. Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignieres B: Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertility Sterility 63: 785-791, 1995
12. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1 (8419): 16-19, 1985
13. Helgason S, Wilking N, Carlstrom K, Damber MG, von Schoultz B: A comparative study of the estrogenic effects of tamoxifen and 17 beta-estradiol in postmenopausal women. J Clin Endocrinol Metab 54: 404-408, 1982
14. Fornander T, Rutqvist LE, Wilking N, Carlstrom K, von Schoultz B: Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. Eur J Cancer 29A: 497-500, 1993
15. Mahoney C: A study of the menstrual cycle in Macacairus with special reference to the detection of ovulation. J Reprod Fertil 21: 153-163, 1970
16. Kaiserman-Abramof I, Padykula H: Utrastructural epithelial zonation of the primate endometrium (rhesus monkey). Am J Anat 184: 13-30, 1989
17. Martel C, Melner MH, Gagne D, Simard J, Labrie F: Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 104 (1): 103-111, 1994
18. Cline JM, Paschold JC, Anthony MS, Obasanjo IO, Adams MR: Effects of hormonal therapies and dietary soy phytoestrogens on vaginal cytology in surgically postmenopausal macaques. Fertility Sterility 65 (5): 1031-1035, 1996
19. Tsubura A, Hatano T, Hayama S, Morii S: Immunophenotypic difference of keratin expression in normal mammary glandular cells from five different species. Acta Anatomica 140: 287-293, 1991
20. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK: Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscl Thromb Vasc Biol 17: 217-221, 1997
21. Williams JK, Wagner JD, Li Z, Golden DL, Adams MR: Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscl Thromb Vasc Biol 17: 403-408, 1997
22. Bowen WH, Koch G: Determination of age in monkeys (Macacairus) on the basis of dental development. Lab Anim 4: 113-123, 1970
23. Wilson ME, Gordon TP, Rudman CG, Tanner JM: Effects of a natural versus artificial environment on the tempo of maturation in female rhesus monkeys. Endocrinology 123: 2653-2661, 1988
24. Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26: 883-888, 1990
25. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357-363, 1992
26. Lindholm J, van Diest PJ, Haffner D, Mikuz G, Wegner AR: A morphometric filter improves the diagnostic value of morphometric analyses of frozen histopathologic sections from mammary tumors. Anal Cell Pathol 4: 443-449, 1992
27. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B: Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 174 (1 Pt 1): 93-100, 1996
28. Colditz GA, Egan KM, Stampfer MJ: Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 168: 1473-1480, 1993
29. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117: 1016-1037, 1992
30. Soderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L: Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 176 (1 Pt 1): 123-128, 1997
31. Goldfine ID, Papa V, Vigneri R, Siiteri P, Rosenthal S: Progestin regulation of insulin and insulin-like growth factor 1 receptors in cultured human breast cancer cells. Breast Cancer Res Treat 22: 69-79, 1992
32. Sutherland RL, Hamilton JA, Sweeney KJ, Watts CK, Musgrove EA: Steroidal regulation of cell cycle progression. Ciba Foundation Symposium 191:218-228; discussion 228-234, 1995
33. Truss M, Beato M: Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endoer Rev 14: 459-479, 1993
34. Kaunitz AM: Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Repr Med 41 (5 Suppl): 419-427, 1996
35. Anonymous: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347 (9017): 1713-1727, 1996
36. Moore MR, Hathaway LD, Bircher JA: Progestin stimulation of thymidine kinase in the human breast cancer cell line T47D. Biochim Biophys Acta 1096: 170-174
37. Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG: Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Ster Biochem Mol Biol 49: 311-318, 1994
38. Nguyen B, Keane MM, Johnston PG: The biology of growth regulation in normal and neoplastic breast epithelium: from bench to clinic. Crit Rev Oncol Hemotol 20: 223-236, 1995
39. Nayfield SG: Tamoxifen's role in chemoprevention of breast cancer: an update. J Cell Biochem - Suppl 22: 42-50, 1995
40. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26: 237-246, 1993
41. Walker KJ, Price-Thomas JM, Candlish W, Nicholson RI: Influence of the antioestrogen tamoxifen on normal breast tissue. Breast J Cancer 64: 764-768, 1991
42. Lundgren S, Soreide JA, Lea OA: Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer. Anticancer Res 14: 1313-1316, 1994